Compare Stocks: TMCI, AORT, BVS, and PRCT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AORT Artivion	$23.19 +0.7%	$26.24	$19.16 ▼ $48.25	$1.13B	1.25	604,740 shs	63,985 shs
BVS Bioventus	$13.90 +2.8%	$13.47	$6.26 ▼ $15.89	$1.16B	0.65	531,873 shs	56,293 shs
PRCT PROCEPT BioRobotics	$17.55 +0.3%	$20.03	$16.67 ▼ $38.11	$1.01B	0.91	1.53 million shs	468,819 shs
TMCI Treace Medical Concepts	$4.57 +0.7%	$4.51	$1.17 ▼ $7.08	$297.62M	1.4	678,955 shs	28,842 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AORT Artivion	-2.03%	-3.62%	-12.58%	-2.55%	-43.72%
BVS Bioventus	-0.66%	+7.05%	-3.98%	+38.24%	+96.23%
PRCT PROCEPT BioRobotics	-3.26%	-10.12%	-18.98%	-22.43%	-53.52%
TMCI Treace Medical Concepts	+0.67%	+0.22%	-5.61%	+1.79%	-33.04%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AORT Artivion	$23.19 +0.7%	$26.24	$19.16 ▼ $48.25	$1.13B	1.25	604,740 shs	63,985 shs
BVS Bioventus	$13.90 +2.8%	$13.47	$6.26 ▼ $15.89	$1.16B	0.65	531,873 shs	56,293 shs
PRCT PROCEPT BioRobotics	$17.55 +0.3%	$20.03	$16.67 ▼ $38.11	$1.01B	0.91	1.53 million shs	468,819 shs
TMCI Treace Medical Concepts	$4.57 +0.7%	$4.51	$1.17 ▼ $7.08	$297.62M	1.4	678,955 shs	28,842 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AORT Artivion	-2.03%	-3.62%	-12.58%	-2.55%	-43.72%
BVS Bioventus	-0.66%	+7.05%	-3.98%	+38.24%	+96.23%
PRCT PROCEPT BioRobotics	-3.26%	-10.12%	-18.98%	-22.43%	-53.52%
TMCI Treace Medical Concepts	+0.67%	+0.22%	-5.61%	+1.79%	-33.04%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AORT Artivion	2.75	Moderate Buy	$44.83	93.32% Upside
BVS Bioventus	2.83	Moderate Buy	$16.80	20.85% Upside
PRCT PROCEPT BioRobotics	2.20	Hold	$25.09	42.97% Upside
TMCI Treace Medical Concepts	1.86	Reduce	$5.17	13.03% Upside

Current Analyst Ratings Breakdown

Latest TMCI, AORT, BVS, and PRCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	PRCT PROCEPT BioRobotics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform
8/31/2026	TMCI Treace Medical Concepts	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/18/2026	AORT Artivion	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$39.00 ➝ $40.00
8/17/2026	BVS Bioventus	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$15.00 ➝ $19.00
8/17/2026	BVS Bioventus	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$15.00
8/14/2026	TMCI Treace Medical Concepts	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	AORT Artivion	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D-)
8/10/2026	TMCI Treace Medical Concepts	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$4.00 ➝ $5.00
8/7/2026	AORT Artivion	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$39.00
8/6/2026	BVS Bioventus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/6/2026	BVS Bioventus	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$18.00

(Data available from 9/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AORT Artivion	$441.33M	2.56	$1.06 per share	21.90	$9.46 per share	2.45
BVS Bioventus	$568.09M	2.06	$1.30 per share	10.70	$2.76 per share	5.04
PRCT PROCEPT BioRobotics	$308.05M	3.26	N/A	N/A	$6.55 per share	2.68
TMCI Treace Medical Concepts	$212.69M	1.40	N/A	N/A	$1.37 per share	3.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AORT Artivion	$9.77M	-$0.07	N/A	30.12	N/A	-0.67%	6.07%	2.93%	11/5/2026 (Estimated)
BVS Bioventus	$22.73M	$0.77	17.95	15.62	1.74	9.36%	28.08%	9.82%	N/A
PRCT PROCEPT BioRobotics	-$95.57M	-$1.94	N/A	N/A	N/A	-32.53%	-30.62%	-22.10%	11/3/2026 (Estimated)
TMCI Treace Medical Concepts	-$59M	-$0.93	N/A	N/A	N/A	-28.99%	-71.37%	-30.49%	11/5/2026 (Estimated)

Latest TMCI, AORT, BVS, and PRCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2026	Q2 2026	TMCI Treace Medical Concepts	-$0.2980	-$0.24	+$0.0580	-$0.24	$44.02 million	$45.38 million
8/6/2026	Q2 2026	AORT Artivion	$0.0025	$0.13	+$0.1275	-$0.28	$119.99 million	$125.76 million
8/5/2026	Q2 2026	BVS Bioventus	$0.22	$0.22	N/A	$0.47	N/A	$153.21 million
8/4/2026	Q2 2026	PRCT PROCEPT BioRobotics	-$0.4619	-$0.47	-$0.0081	-$0.47	$92.77 million	$94.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AORT Artivion	N/A	N/A	N/A	N/A	N/A
BVS Bioventus	N/A	N/A	N/A	N/A	N/A
PRCT PROCEPT BioRobotics	N/A	N/A	N/A	N/A	N/A
TMCI Treace Medical Concepts	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AORT Artivion	0.82	3.47	2.51
BVS Bioventus	0.83	1.69	1.17
PRCT PROCEPT BioRobotics	0.15	6.55	5.35
TMCI Treace Medical Concepts	0.83	2.90	1.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AORT Artivion	86.37%
BVS Bioventus	62.94%
PRCT PROCEPT BioRobotics	89.46%
TMCI Treace Medical Concepts	84.08%

Insider Ownership

Company	Insider Ownership
AORT Artivion	6.30%
BVS Bioventus	33.50%
PRCT PROCEPT BioRobotics	4.00%
TMCI Treace Medical Concepts	23.42%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AORT Artivion	1,800	48.76 million	45.68 million	Optionable
BVS Bioventus	950	84.09 million	55.92 million	N/A
PRCT PROCEPT BioRobotics	888	57.27 million	54.98 million	Optionable
TMCI Treace Medical Concepts	450	65.04 million	49.80 million	Optionable

TMCI, AORT, BVS, and PRCT Headlines

Recent News About These Companies

Critical Comparison: Treace Medical Concepts (NASDAQ:TMCI) versus TransMedics Group (NASDAQ:TMDX)

September 24 at 5:44 AM | americanbankingnews.com

Treace Medical (TMCI) Reports Five-Year Bunion Results. Can Evidence Drive Adoption?

September 22 at 10:51 PM | insidermonkey.com

Analyzing LogicMark (OTCMKTS:LGMKD) and Treace Medical Concepts (NASDAQ:TMCI)

September 21, 2026 | americanbankingnews.com

Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D(R) Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty(R) Procedure

September 18, 2026 | marketscreener.comM

Treace Medical Concepts, Inc.: Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D Study Demonstrating Sustained, Positive Outcomes of the ...

September 18, 2026 | finanznachrichten.de

Treace Medical Concepts Presents 5-Year ALIGN3D, 2-Year MTA3D and SPRINT Clinical Study Results at AOFAS Annual Meeting

September 17, 2026 | quiverquant.comQ

Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D® Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure

September 17, 2026 | globenewswire.com

Treace Highlights Foot & Ankle Portfolio Updates At 2026 AOFAS Annual Meeting

September 16, 2026 | rttnews.com

Treace Medical Concepts to Showcase New Foot and Ankle Innovations and Clinical Data at AOFAS 2026

September 15, 2026 | quiverquant.comQ

Treace Highlights Product Innovations and Clinical Data Across its Expanding Foot & Ankle Portfolio at the 2026 AOFAS Annual Meeting

September 15, 2026 | globenewswire.com

BlackRock Inc. Takes Position in Treace Medical Concepts, Inc. $TMCI

September 6, 2026 | marketbeat.com

Treace Medical Concepts, Inc. (NASDAQ:TMCI) Given Consensus Recommendation of "Reduce" by Analysts

September 5, 2026 | marketbeat.com

Bank of America Corp DE Has $4.31 Million Stock Holdings in Treace Medical Concepts, Inc. $TMCI

August 29, 2026 | marketbeat.com

Treace Medical Concepts (NASDAQ:TMCI) CEO John Treace Buys 5,000 Shares

August 25, 2026 | insidertrades.com

Treace Medical Concepts Earnings Call Signals Cautious Rebound

August 18, 2026 | tipranks.com

Treace Medical (TMCI) Q2 2026 Earnings Call Transcript

August 14, 2026 | finance.yahoo.com

Treace Medical Concepts, Inc. Q2 2026 Earnings Call Summary

August 8, 2026 | finance.yahoo.com

Treace Medical Concepts: Q2 Earnings Snapshot

August 7, 2026 | seattlepi.comS

Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates

August 7, 2026 | zacks.com

Treace Medical Concepts Reports Second Quarter 2026 Financial Results

August 7, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TMCI, AORT, BVS, and PRCT Company Descriptions

Artivion NYSE:AORT

$23.19 +0.16 (+0.70%)

As of 12:07 PM Eastern

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Bioventus NASDAQ:BVS

$13.90 +0.38 (+2.82%)

As of 12:08 PM Eastern

Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

PROCEPT BioRobotics NASDAQ:PRCT

$17.55 +0.05 (+0.29%)

As of 12:08 PM Eastern

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

Treace Medical Concepts NASDAQ:TMCI

$4.57 +0.03 (+0.75%)

As of 12:07 PM Eastern

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TMCI, AORT, BVS, and PRCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TMCI, AORT, BVS, and PRCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TMCI, AORT, BVS, and PRCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TMCI, AORT, BVS, and PRCT Company Descriptions

Artivion NYSE:AORT

Bioventus NASDAQ:BVS

PROCEPT BioRobotics NASDAQ:PRCT

Treace Medical Concepts NASDAQ:TMCI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TMCI, AORT, BVS, and PRCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TMCI, AORT, BVS, and PRCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TMCI, AORT, BVS, and PRCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TMCI, AORT, BVS, and PRCT Company Descriptions

Artivion NYSE:AORT

Bioventus NASDAQ:BVS

PROCEPT BioRobotics NASDAQ:PRCT

Treace Medical Concepts NASDAQ:TMCI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools